Effect of Vitamin E+Selenium on Kidney Function in Controlled Hypotension

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Tehran University of Medical Sciences.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Zahed Hosein Khan, Tehran University of Medical Sciences
ClinicalTrials.gov Identifier:
First received: February 19, 2012
Last updated: March 13, 2012
Last verified: March 2012
The purpose of this study is to determine whether Kidney injury happens in controlled hypotension during brain operations by using Neutrophil Gelatinase Associated Lipocalin ELISA Kit and if so, does VitaminE+Selenium prevent it

Condition Intervention Phase
Acute Kidney Injury
Drug: vitamin E +Selenium
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Assessment of Preventive Effect of Vitamin E +Selenium on Acute Kidney Injury Through NGAL in Patients Undergoing Controlled Hypotension During Neurosurgery Operations

Resource links provided by NLM:

Further study details as provided by Tehran University of Medical Sciences:

Primary Outcome Measures:
  • increased amount of urinary or serum NGAL after controlled hypotension [ Time Frame: from 2 hours to 24 hours after controlled hypotension ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 60
Study Start Date: June 2011
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: vitamin E +Selenium
    vitamin E 400 IU once 8 hrs before operation selenium 150 mic once 8 hrs before operation
Detailed Description:
NGAL(Neutrophil Gelatinase Associated Lipocalin) is a 25KD protein which bounds with Gelatinase in Neutrophil granules.It is also expressed in epithelial cells of kidney tubules.NGAL increases in ischemic and toxic injuries of kidney. During controlled hypotension in brain operations injury to the kidneys might occur . This study is designed to assess this possibility and evaluate the effect of VitaminE+Selenium on prevention of this problem

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • All patients who are candidate for brain surgery under controlled hypotension

Exclusion Criteria:

  • Positive history of renal disease
  • Positive history of diabetes mellitus, CHF, HTN, Breast cancer, fever, leukocytosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01554345

Contact: Mahmoodreza Torkaman, resident 0098 917 105 0954 MRZTORKAMAN@yahoo.com

Iran, Islamic Republic of
Tehran university of medical sciences, Imam Khomeini Hospital, neurosurgery operation room and ward Recruiting
Tehran, Iran, Islamic Republic of
Contact    0098 21 6119 2828    roaf2009@yahoo.com   
Principal Investigator: Mahmoodreza Torkaman, Resident         
Sponsors and Collaborators
Tehran University of Medical Sciences
  More Information

Responsible Party: Zahed Hosein Khan, professor, Tehran University of Medical Sciences
ClinicalTrials.gov Identifier: NCT01554345     History of Changes
Other Study ID Numbers: 89-04-30-11624 
Study First Received: February 19, 2012
Last Updated: March 13, 2012
Health Authority: Iran: Ethics Committee
United States: Food and Drug Administration

Additional relevant MeSH terms:
Vitamin E
Acute Kidney Injury
Cardiovascular Diseases
Kidney Diseases
Renal Insufficiency
Urologic Diseases
Vascular Diseases
Growth Substances
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Protective Agents
Trace Elements

ClinicalTrials.gov processed this record on May 30, 2016